REVIEW

A Systematic Review and Meta-Analysis of Intraperitoneal Bupivacaine in Laparoscopic **Gynecologic Surgery**

Greg Marchand (D) Kelly Ware^{1,2} Malini Govindan¹ Ahmed T Masoud^{1,3} Alexa King^{1,2} Stacy Ruther¹ Giovanna Brazil¹ Kaitlynne Cieminski¹ Nicolas Calteux Catherine Coriell¹ Hollie Ulibarri¹ Julia Parise¹ Amanda Arroyo¹ Diana Chen⁴ Maria Pierson⁴ Rasa Rafie⁵ Katelyn Sainz¹

¹Marchand Institute for Minimally Invasive Surgery, Mesa, AZ, USA; ²International University of Health Sciences, Basseterre, St. Kitts; ³Fayoum University Faculty of Medicine, Fayoum, Egypt; ⁴Midwestern University College of Osteopathic Medicine, Glendale, AZ, USA; ⁵Rocky Vista University College of Osteopathic Medicine, Parker, CO, USA

Correspondence: Greg Marchand Marchand Institute for Minimally Invasive Surgery, 10238 E. Hampton, Ste. 212, Mesa, AZ, 85209, USA Tel +1 4809990905 Fax +1 4809990801 Email gm@marchandinstitute.org

Objective: We set out to evaluate whether the instillation of bupivacaine versus a saline solution into the peritoneal cavity at time of laparoscopic gynecologic surgery will reduce postoperative pain and postoperative opioid consumption.

Data Sources: We searched six databases: Web of Science, SCOPUS, Cochrane CENTRAL, ClinicalTrials.Gov, MEDLINE and PubMed. Our search strategy had no restriction on time or languages and included all studies that met our search algorithm up to March of 2021.

Methods of Study Selection: We included only randomized trials that met our search strategy for the outcomes of 1) pain intensity 24 hours after surgery, 2) pain intensity 6 hours after surgery, and 3) length of hospital stay.

Tabulation, Integration, and Results: We analyzed continuous data using mean difference (MD) with relative 95% confidence interval (CI). We included 8 randomized clinical trials. We found that intraperitoneal bupivacaine showed significant difference from the saline group regarding pain intensity 24 hours after surgery (MD= -0.73 [-1.10, -0.36]) (P = 0.01) and pain intensity 6 hours after surgery (MD= -1.12 [-2.22, -0.02]) (P = 0.05). Overall, patients allocated to the placebo group seemed to need other analgesics earlier than patients allocated to the bupivacaine group (MD=145.08 [51.37, 238.79] (P = 0.02)). There was no significant difference regarding the length of hospital stay (MD=-0.44 [-1.44, 0.56]) (P = 0.39).

Conclusion: Bupivacaine significantly reduced the visual analog pain score for pain compared with that of the placebo at 6 and 24 hours postoperatively. There was no significant difference in hospital stay.

Prospero Registration: CRD42021254268.

Keywords: ERAS, marcaine, bupivacaine, enhanced recovery after surgery, intra-abdominal anesthetic

Introduction

Gynecologic surgery is very prevalent in the United States, comprising 26.5% of all surgeries performed on women.¹ Postoperative pain is one of the most important complications of gynecologic surgeries. Approximately 86% of patients suffer from postoperative pain, and about 75% of those report that the pain is moderate to severe.² Improvements in postoperative pain management could lead to shorter hospital stays, decreased costs, earlier mobilization and prevention of thrombosis, and decreased morbidity.^{3,4} Chronic postoperative pain increases sympathetic tone, which in turn may increase molecular catabolism, resulting in abnormal muscle functioning.⁵ Substantial pain after laparoscopic gynecologic surgeries may require

Journal of Pain Research 2021:14 2699-2707 © 2021 Marchand et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com. the work you hereby accept the Ierms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). large doses of opioids in the first 24 hours after the procedure, which can lead to the additional complications of opioid tolerance and habituation.⁶ Several authors have suggested that the administration of local analgesics may reduce the total need for opioids in the first 24 hours postoperatively.⁷ Preemptive anesthesia has been attempted in many forms, including local injection at the surgery site, epidural, or in a systematic manner just before surgical incision.^{8,9} Local anesthetics can also be injected at incisional sites and placed intraperitoneal in an attempt to decrease both visceral and somatic pain.¹⁰

Despite the fact that many different local anesthetics have been attempted in the preoperative, intraoperative, and postoperative periods, there remains no clear consensus as to the best local anesthetic or the best route of administration.^{11,12} Some authors have suggested simply pouring local anesthetics into the abdominal cavity, as the majority of the patient's pain in the postoperative period does seem deep in the abdomen following laparoscopy.¹³ Some authors have discussed that this method may decrease patient safety as abdominal anesthetics likely have higher intravascular absorption than other methods of administration.¹⁴ Cases of toxicity have been reported, a specific syndrome of local anesthetic systemic toxicity (LAST) has been described.¹⁴

Bupivacaine is a long acting, potent local anesthetic agent that is commonly used in gynecologic surgery.^{15–18} In this meta-analysis, we evaluate whether the intraperitoneal placement of a bupivacaine solution versus a saline solution reduces postoperative pain in women undergoing laparoscopic gynecologic surgery, and whether there is a decrease in hospital stay, or time until first required opioid administration.

Methods

Strict adherence was undertaken in every stop of our metaanalysis and systematic review. As guidelines for this undertaking we used the checklist for "Preferred Reporting Items for Systematic Reviews and Meta-analyses" (PRISMA), and followed all steps to the letter.¹⁹ Every step of this systematic review was also performed in complete concordance with the instructions included in Cochrane's "handbook of systematic reviews of interventions".²⁰

Literature Search

We searched Web of Science, SCOPUS, Cochrane CENTRAL, ClinicalTrials.Gov, MEDLINE and PubMed, for published trials without any restrictions on time or languages. We used the following search strategy: (marcaine OR Bupivacaine OR Sensorcaine OR Posimir) AND ("gynecologic surgery").

Inclusion Criteria

The following five criteria were utilized to define eligibility: (I) Patient Population: all female patients undergoing a laparoscopic gynecologic surgery. (ii) Intervention: Bupivacaine (iii) comparator: Placebo. (IV) Outcomes: Pain intensity 24 hours after surgery, Pain intensity 6 hours after surgery, elapsed time for the first non-local analgesic dose, and length of hospital stay. (v) Study design: Only randomized controlled trials were included in our study (RCTs). We excluded any clinical trials that were non-randomized, trials that did not measure for our selected outcomes, studies whose participants were healthy volunteers without surgical intervention, studies without a control group, and animal studies.

Screening of Results

We scanned the reference list of retrieved studies using Endnote software. Following the automatic deletion of all duplicate studies, we looked at the remaining studies using a two step process. This included first looking at the abstract, and then only moving on to a full text screening on those articles that were found in the first step to meet our criteria.

Data Extraction and Analysis

Two independent authors extracted the data from the included studies. We extracted the data of all of the major categories required in this work. This included 3 basic categories of data as follows:

1) Demographic data of the patients in each of the included studies. This included body mass index (BMI), patient age, surgery performed, and the duration of the surgery in minutes.

2) Outcome data for our meta-analysis: Pain intensity 24 hours after surgery, pain intensity 6 hours after surgery, elapsed time until the first analgesic dose, and length of hospital stay.

3) Data about the risk of bias from each study, in order to complete Cochrane's risk of bias analysis of our review.

Analysis of Data

RevMan (version 5.4.1) was utilized in order to perform the meta-analysis. The inverse variance method was used. Data for continuous outcomes were extracted and pooled using the techniques of mean difference (MD) and standard deviation,

relative to a ninety-five percent confidence interval (CI), while data for those outcomes which were dichotomous were extracted and reported using percent and total. We assessed heterogeneity among studies²¹ by visual inspection of the forest plots, the I-square test (I2), and the P-value of the Chi-square test. The overall analysis of outcomes in the cases where I² > 50%, P<0.1 were considered heterogeneous, and those values where I² < 50%, P>0.1 were considered homogeneous, as is suggested in adhering to the "The Cochrane Handbook".²⁰ We performed an analysis of the homogeneous outcomes under a fixed-effects model using the Mantel Haenszel (M-H) method, while those outcomes that were heterogeneous were analyzed using the "random-effects" model.

Quality Assessment

To assess the risk of bias of the included randomized clinical trials, we conducted the quality assessment of this study according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). We used Cochrane's risk of bias assessment tool²² which includes the following domains: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selection outcome reporting (reporting bias), and other potential sources of bias.

Results

Summary of Included Clinical Trials

The electronic search results are described in detail in Figure 1, which shows a PRISMA diagram of our search and screening process. We performed the analysis of 532 patients undergoing different laparoscopic gynecological surgeries from eight studies,^{23–30} with a total of 265 patients allocated to the bupivacaine group, and 267 patients allocated to the placebo group. The average age of participants in the bupivacaine group was 37.08 years and the average age of the placebo group was 37.58 years. Table 1 shows a complete summary of the included patients, including their demographic data, body mass index (BMI), and the duration of surgery.

Results of Risk of Bias Assessment

The overall quality assessment was a low risk of bias according to Cochrane's tool.²⁰ All studies^{23–30} were at low risk of bias regarding randomization, blinding of participants and personnel, attrition, and selective reporting bias. Concerning allocation concealment, 5 studies^{23,25–27,30} reported proper allocation concealment, and therefore they were judged to be at low risk of bias. Three studies^{24,28,29} did not report enough data about concealment so they were categorized as an unclear risk of bias. Concerning blinding of outcome assessment, three studies^{23,27,30} revealed adequate blinding of the outcome assessors so they were categorized as low risk of bias, while the remaining studies^{24–26,28,29} were categorized as an unclear risk of bias. Supplemental File 1 shows an illustration of the individual risks of bias of the included studies.

Analysis of Outcomes

Pain Intensity 24 Hours After Surgery

Six studies^{23,24,26,27,29,30} reported VAS pain scores after 24 hours. The overall estimate favored the bupivacaine group significantly (MD= -0.73 [-1.10, -0.36], (P = 0.01)). We found significant heterogeneity (P = 0.01); I² = 66% (Figure 2A). In order to solve heterogeneity, we excluded Badawy 2017^{24} (P = 0.12); I² = 45%. Pooled analysis after solving heterogeneity also favored the bupivacaine group significantly (MD= -0.66 [-0.93, -0.39], (P = 0.01)) (Figure 2B).

Pain Intensity 6 Hours After Surgery

Five studies^{23,24,28–30} reported VAS pain scores after six hours. Pooled analysis showed that bupivacaine was superior to placebo in reducing pain after six hours (MD= -1.12 [-2.22, -0.02], P = 0.05). Data was heterogeneous (P = 0.03); I² = 81% as shown in Figure 3A. We solved the heterogeneity by excluding Arden et al²³ (P = 0.59); I² = 0%. The combined analysis after solving heterogeneity also favored the bupivacaine group significantly (MD= -1.85 [-2.15, -1.55]) as shown in Figure 3B.

Length of Hospital Stay (Hours)

Two studies^{23,27} reported the length of hospital stay. The overall estimate showed no significant difference between either group (MD= -0.44 [-1.44, 0.56], (P = 0.39)). No significant heterogeneity was found between studies (P = 0.27); I² = 16% as shown in Figure 4.

Elapsed Time Prior to the First Non-Local Analgesic Dose (in Minutes)

Three studies estimated the elapsed time prior to the first non-local analgesic dose,^{24–26} and the analysis showed that patients allocated to placebo group needed analgesics earlier than patients allocated to bupivacaine group (MD=145.08 [51.37, 238.79], (P = 0.02)). Pooled analysis was heterogeneous (P < 0.01); I² = 97%) as seen in




Figure I Shows a PRISMA flow diagram of our literature search.

Figure 5A. We solved heterogeneity by leaving out Karsli et al 2003^{25} (P = 0.50); I² = 0%. The analysis after solving heterogeneity also favored bupivacaine the group significantly (MD=192.54 [167.25, 217.84], (P < 0.01)) as shown in Figure 5B.

Discussion

In this systematic review, we included 8 randomized clinical trials that evaluated the effect of intra-abdominal local analgesic on postoperative pain after various laparoscopic gynecological surgeries. Our meta-analysis showed a significant reduction in VAS score for pain in the bupivacaine group compared with that of the placebo at 6 and 24 hours postoperatively.

A previous meta-analysis performed by Marks et al³¹ suggested that intraperitoneal local analgesia was very effective in the reduction of postoperative pain at 2 and 6 hours after Laparoscopic Gynecologic surgery, and that bupivacaine did not seem to have any major side effects. These results were consistent with our findings. The major

Study	Sample	Size	Age, Years (N	1ean ± SD)	BMI (K	g/m2)	Operation Time (mins)		
	Bupivacaine	Control	Bupivacaine	Placebo	Bupivacaine	Placebo	Bupivacaine	Placebo	
Arden 2013 ²³	80	80	44.1±6.4	44.9±7.1	28.4±7.6	27.4±5.9	24.7±34.	126.7±35	
Badawy 2017 ²⁴	10	10	46.40±3.21	46.20±4.32	31.60±1.14	30.00±2.67	132.00±30.33	137.00±41.65	
Butala 2013 ²⁶	30	30	34.3±9.26	33.7±7.69	NR	NR	114.7±40.88	115.3±16.28	
Chou 2005 ²⁷	30	31	31.6±7.9	35.1±11.0	22.8±3.5	21.5±3.7	96.42±29.44	88.96±30.08	
Karsli 2003 ²⁵	20	20	38.7±7.8	39.8±8.3	NR	NR	48.9±12.5	45.0±9.0	
Kayacan 2002 ²⁸	20	20	38.7 ± 7.8	38.7 ± 7.8	NR	NR	48.9 ± 12.5	45.0 ± 9.0	
Keita 2003 ²⁹	15	16	31.8±5.6	32.5±5.2	NR	NR	68.2±49.6	56.5±35.6	
Shalan 2002 ³⁰	60	60	31.1 ± 4.2	29.8 ± 3.7	NR	NR	NR	NR	

Table I Detailed Summary of the Included Participants, Their Demographic Data, and Types of Operations

Note: Data are reported as mean ± SD.

Abbreviations: NR, not reported; BMI, body-mass index.

limitation of this previous meta-analysis was the relatively small number of patients. Therefore, analyzing the data nine years later, we were able to include far more trials in the present meta-analysis to provide large-scale evidence of the effect of intraperitoneal bupivacaine on postoperative pain.

Multiple trials have shown a benefit to the subcutaneous injection of bupivacaine into tissues around the wound in a technique similar to using lidocaine for local short-acting anesthesia.^{26,32–34} These studies have ranged from small cohort studies to large RCT's and looked at fractionated and unfractionated forms, as well as preoperative and postoperative administration.^{33–36} Therefore, it would make sense that intraperitoneal bupivacaine could also be beneficial.

Lastly, a major impetus of this study was the sediment from our authors that postoperative pain from gynecologic surgeries, especially laparoscopic and vaginal hysterectomy, from the perspective of any experienced surgery is intra-abdominal pain. Examination of these patients soon after surgery shows tender abdomens that do not tolerate deep examination, it does not show point tenderness to superficial wounds, as one might commonly see, for example, with a herpes or shingles lesion. Therefore the superiority of intraperitoneal bupivacaine to subcutaneous or local injection, to our authors, seems obvious.

Α	Bup	ivacai	ne	PI	acebo			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
Arden 2013	2.6	2.6	65	2.4	2.5	41	10.2%	0.20 [-0.79, 1.19]	+		
Badawy 2017	3.9	0.89	10	6.1	1.37	10	9.9%	-2.20 [-3.21, -1.19]	-		
Butala 2013	2.3	0.7	30	3.1	0.2	30	31.6%	-0.80 [-1.06, -0.54]			
Chou 2005	1.17	1.47	26	1.16	1.61	27	13.1%	0.01 [-0.82, 0.84]	+		
Keita 2003	10	18.5	15	10	14.8	16	0.1%	0.00 [-11.84, 11.84]			
Shalan 2002	0.3	0.45	60	1.1	0.45	60	35.0%	-0.80 [-0.96, -0.64]			
Total (95% CI)			206			184	100.0%	-0.73 [-1.10, -0.36]	•		
Heterogeneity: Tau ² =	= 0.10; C	hi ² = 1	4.88, d	f= 5 (P =	= 0.01); I ² = 6	6%	-			
Test for overall effect: Z = 3.84 (P = 0.0001)							-10 -5 Ó Ś 10 Bupivacaine Placebo				
B	Bupivacaine			Pla	acebo			Mean Difference	Mean Difference		
	Cap	rucun							Inour Dinoronoo		
Study or Subgroup	Mean			Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI		
						Total 41	Weight 6.6%				
Arden 2013	Mean	SD	Total	Mean	SD			IV, Random, 95% CI			
Arden 2013 Badawy 2017	Mean 2.6	SD 2.6	Total 65	Mean 2.4	SD 2.5	41	6.6%	IV, Random, 95% CI 0.20 [-0.79, 1.19]			
Arden 2013 Badawy 2017 Butala 2013	Mean 2.6 3.9	SD 2.6 0.89 0.7	Total 65 10	Mean 2.4 6.1	SD 2.5 1.37	41 10	6.6% 0.0%	IV, Random, 95% Cl 0.20 [-0.79, 1.19] -2.20 [-3.21, -1.19]			
Study or Subgroup Arden 2013 Badawy 2017 Butala 2013 Chou 2005 Keita 2003	Mean 2.6 3.9 2.3 1.17	SD 2.6 0.89 0.7	Total 65 10 30	Mean 2.4 6.1 3.1	SD 2.5 1.37 0.2	41 10 30	6.6% 0.0% 37.2%	IV, Random, 95% CI 0.20 [-0.79, 1.19] -2.20 [-3.21, -1.19] -0.80 [-1.06, -0.54]			
Arden 2013 Badawy 2017 Butala 2013 Chou 2005 Keita 2003	Mean 2.6 3.9 2.3 1.17 10	SD 2.6 0.89 0.7 1.47	Total 65 10 30 26	Mean 2.4 6.1 3.1 1.16	SD 2.5 1.37 0.2 1.61	41 10 30 27	6.6% 0.0% 37.2% 9.0%	IV, Random, 95% CI 0.20 [-0.79, 1.19] -2.20 [-3.21, -1.19] -0.80 [-1.06, -0.54] 0.01 [-0.82, 0.84]			
Arden 2013 Badawy 2017 Butala 2013 Chou 2005	Mean 2.6 3.9 2.3 1.17 10	SD 2.6 0.89 0.7 1.47 18.5	Total 65 10 30 26 15	Mean 2.4 6.1 3.1 1.16 10	SD 2.5 1.37 0.2 1.61 14.8	41 10 30 27 16 60	6.6% 0.0% 37.2% 9.0% 0.1%	IV, Random, 95% CI 0.20 [-0.79, 1.19] -2.20 [-3.21, -1.19] -0.80 [-1.06, -0.54] 0.01 [-0.82, 0.84] 0.00 [-11.84, 11.84]			
Arden 2013 Badawy 2017 Butala 2013 Chou 2005 Keita 2003 Shalan 2002	Mean 2.6 3.9 2.3 1.17 10 0.3	SD 2.6 0.89 0.7 1.47 18.5 0.45	Total 65 10 30 26 15 60 196	Mean 2.4 6.1 3.1 1.16 10 1.1	SD 2.5 1.37 0.2 1.61 14.8 0.45	41 10 30 27 16 60 174	6.6% 0.0% 37.2% 9.0% 0.1% 47.2% 100.0%	IV, Random, 95% CI 0.20 [-0.79, 1.19] -2.20 [-3.21, -1.19] -0.80 [-1.06, -0.54] 0.01 [-0.82, 0.84] 0.00 [-11.84, 11.84] -0.80 [-0.96, -0.64]			

Figure 2 (A and B) show forest plots of patient pain at 24 hours after surgery, before (A) and after (B) removing Badawy et al 2017 to solve heterogeneity.

Α	Bupi	vacair	ie	Pla	acebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Arden 2013	3	2.4	64	2.9	2.4	70	26.9%	0.10 [-0.71, 0.91]	+
Badawy 2017	6.2	0.84	10	7.8	1.55	10	24.0%	-1.60 [-2.69, -0.51]	
kayacan 2002	4.7	2.36	20	5.4	3.48	20	16.7%	-0.70 [-2.54, 1.14]	
Keita 2003	3.3	7.4	15	6.7	14.8	16	1.7%	-3.40 [-11.56, 4.76]	
Shalan 2002	1.2	0.75	60	3.1	1	60	30.7%	-1.90 [-2.22, -1.58]	
Total (95% CI)			169			176	100.0%	-1.12 [-2.22, -0.02]	•
Test for overall effect: B									-10 -5 Ó 5 10 Bupivacaine Placebo
	Bupivacaine		Placebo						
								Mean Difference	Mean Difference
Study or Subgroup	Mean				acebo SD		Weight	Mean Difference IV, Random, 95% Cl	IV, Random, 95% Cl
							Weight 0.0%	IV, Random, 95% CI	
Study or Subgroup	Mean	SD 2.4	Total	Mean	SD	Total		IV, Random, 95% CI	
Study or Subgroup Arden 2013	Mean 3	SD 2.4 0.84	Total 64	Mean 2.9	SD 2.4	Total 70	0.0%	IV, Random, 95% CI 0.10 [-0.71, 0.91]	
Study or Subgroup Arden 2013 Badawy 2017	Mean 3 6.2	SD 2.4 0.84 2.36	Total 64 10	Mean 2.9 7.8	SD 2.4 1.55	Total 70 10	0.0% 7.5% 2.6%	IV, Random, 95% CI 0.10 [-0.71, 0.91] -1.60 [-2.69, -0.51] -0.70 [-2.54, 1.14]	
Study or Subgroup Arden 2013 Badawy 2017 kayacan 2002	Mean 3 6.2 4.7 3.3	SD 2.4 0.84 2.36	Total 64 10 20	Mean 2.9 7.8 5.4	SD 2.4 1.55 3.48	Total 70 10 20	0.0% 7.5% 2.6%	IV, Random, 95% CI 0.10 [-0.71, 0.91] -1.60 [-2.69, -0.51] -0.70 [-2.54, 1.14]	
Study or Subgroup Arden 2013 Badawy 2017 kayacan 2002 Keita 2003	Mean 3 6.2 4.7 3.3	SD 2.4 0.84 2.36 7.4	Total 64 10 20 15	Mean 2.9 7.8 5.4 6.7	SD 2.4 1.55 3.48	Total 70 10 20 16	0.0% 7.5% 2.6% 0.1% 89.7%	IV, Random, 95% Cl 0.10 [-0.71, 0.91] -1.60 [-2.69, -0.51] -0.70 [-2.54, 1.14] -3.40 [-11.56, 4.76] -1.90 [-2.22, -1.58]	
Study or Subgroup Arden 2013 Badawy 2017 kayacan 2002 Keita 2003 Shalan 2002	Mean 3 6.2 4.7 3.3 1.2	SD 2.4 0.84 2.36 7.4 0.75	Total 64 10 20 15 60 105	Mean 2.9 7.8 5.4 6.7 3.1	SD 2.4 1.55 3.48 14.8 1	Total 70 10 20 16 60 106	0.0% 7.5% 2.6% 0.1% 89.7% 100.0%	IV, Random, 95% Cl 0.10 [-0.71, 0.91] -1.60 [-2.69, -0.51] -0.70 [-2.54, 1.14] -3.40 [-11.56, 4.76] -1.90 [-2.22, -1.58]	

Figure 3 (A and B) show forest plots of patient pain at 6 hours after surgery, before (A) and after (B) removing Arden et al 2013 to solve heterogeneity.

	Bupi	vacai	ne	Placebo				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Arden 2013	22.9	3.2	76	23.4	3.2	80	98.8%	-0.50 [-1.50, 0.50]	
Chou 2005	41.27	16.6	26	36.56	17.86	27	1.2%	4.71 [-4.57, 13.99]	
Total (95% CI)			102			107	100.0%	-0.44 [-1.44, 0.56]	•
Heterogeneity: Chi ² =	1.20, df	= 1 (P	= 0.27)); I ^z = 16	%				-10 -5 0 5 10
Test for overall effect:	Z = 0.86	(P = 0).39)						Bupivacaine Placebo

Figure 4 Shows the forest plot of the outcomes for length of hospital stay.

Α	Bug	pivaca	ine	P	lacebo)		Mean Difference		Mean Difference		
Study or Subgroup	Mean	SD	SD Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% (1	
Badawy 2017	360	84.6	10	192	88.8	10	29.2%	168.00 [91.98, 244.02]				
Butala 2013	270.8	56.8	30	75	48.9	30	35.0%	195.60 [168.78, 222.42]				
Karsli 2003	93	29	20	16	9.1	20	35.8%	77.00 [63.68, 90.32]				
Total (95% CI)			60	6		60	100.0%	145.08 [51.37, 238.79]		-	-	
Heterogeneity: Tau ² Test for overall effect					2 (P <)	0.0000	1); l ² = 97	%	-500	-250 0 Placebo Bupivao	250 500 aine	
В	Bupivacaine Placebo					Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% C	1	
Badawy 2017	350	84.6	10	192	88.8	10	11.1%	168.00 [91.98, 244.02]				
Butala 2013	270.6	56.8	30	75	48.9	30	88.9%	195.60 [168.78, 222.42]				
Karsli 2003	93	29	20	16	9.1	20	0.0%	77.00 [53.68, 90.32]				
Total (95% CI)			40			40	100.0%	192.54 [167.25, 217.84]				
Heterogeneity: Tau* =	0.00; CI	hi*= 0.	45, df=	1 (P=	0.50);1	P= 0%			+		ato cot	
Test for overall effect:	Z=14.9	2 (P <	0.0000	1)					-500	-250 0 Placebo Bupivaca	260 500 line	

Figure 5 (A and B) show forest plots of the elapsed time prior to the first non-local analgesic dose, before (A) and after (B) removing Karsli et al 2003 to solve heterogeneity.

Strengths

The major strength of our study was our inclusion of only those clinical trials which were properly randomized and controlled for. According to the GRADE guideline, this should provide the highest level of evidence. Another strength of our study was the risk of bias, as all of the included studies were judged to be at a low risk of bias, almost universally in all categories. Next, our patient sample size in the included studies was quite large, including 534 total patients. This speaks to higher quality evidence. Lastly, we were able to solve the heterogeneity that was found in our results using only appropriate, recognized techniques that can be found within Cochrane's handbook.²²

Limitations

Although the biggest single limitation facing this study was the heterogeneity in some of our outcomes, we were able to track down the individual attributing factors and solve the heterogeneity in all cases. Another limitation includes the inherent weaknesses of subjective pain scales such as the VAS,³⁷ although our authors do not have a better system to propose at this time. Lastly, although our goal was to find the existence of an effect, the fact that the doses used were not standardized is another weakness of our study.

Conclusion

We conclude that intraperitoneal bupivacaine significantly reduced the VAS score for pain compared with that of the placebo at 6 and 24 hours. This efficacy may lead surgeons to consider intraperitoneal administration in laparoscopic gynecologic surgical procedure. Further studies are needed to determine the best local anesthetic and route of administration for minimization of postoperative pain in laparoscopic gynecologic surgery.

Data Sharing Statement

All supporting data is included or referenced in this manuscript. The authors have no additional data used in this study.

Ethics Approval and Consent to Participate

This Manuscript has been reviewed by the institutional IRB board at Marchand Institute and was found to be exempt from IRB review (March 2021). Data used was exempt from consent to participate or publish secondary to

the nature of the study being a systematic review, retrospectively looking at previously published data.

Consent to Publish

Data used was exempt from consent to participate or publish secondary to the nature of the study being a systematic review, retrospectively looking at previously published data.

Patient Consent

Not applicable to systematic review.

Acknowledgments

The Marchand Institute for Minimally Invasive Surgery would like to acknowledge the efforts of all of the students, researchers, residents and fellows at the institute who put their time and effort into these projects without compensation, only for the betterment of women's health. We firmly assure them that the future of medicine belongs to them.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding

No funding was received for this study.

Disclosure

The authors declare no competing interests.

References

- Ismail S, Siddiqui AS, Rehman A. Postoperative pain management practices and their effectiveness after major gynecological surgery: an observational study in a tertiary care hospital. *J Anaesthesiol Clin Pharmacol.* 2018;34(4):478. doi:10.4103/joacp.JOACP_387_17
- Brandsborg B, Nikolajsen L, Hansen CT, Kehlet H, Jensen TS. Risk factors for chronic pain after hysterectomy: a nationwide questionnaire and database study. *Anesthesiology*. 2007;106(5):1003–1012. doi:10.1097/01.anes.0000265161.39932.e8
- 3. Lovich-Sapola J, Smith CE, Brandt CP. Postoperative pain control. Surg Clin North Am. 2015;95(2):301–318. doi:10.1016/j. suc.2014.10.002
- Garimella V, Cellini C. Postoperative pain control. *Clin Colon Rectal* Surg. 2013;26(03):191–196. doi:10.1055/s-0033-1351138
- Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. *J Pain Res.* 2017;10:2287–2298. doi:10.2147/JPR.S144066

- Kinsella S, Gibbison B. Postoperative analgesia for gynecological laparoscopy. Saudi J Anaesth. 2009;3(2):26. doi:10.4103/1658-354X.57883
- Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. *Anesth Analg.* 2017;125(5):1733–1740. doi:10.1213/ANE.00000000002458
- Winacoo JN, Maykel JA. Operative anesthesia and pain control. *Clin Colon Rectal Surg.* 2009;22(01):041–046. doi:10.1055/s-0029-1202885
- Elsevier H, Cannada LK. Management of pain associated with fractures. *Curr Osteoporos Rep.* 2020;18(3):130–137. doi:10.1007/ s11914-020-00578-3
- Shady NW, Sallam HF, Ali SS, Abbas AM. Effect of intra-peritoneal and incisional port site lidocaine on pain relief after gynecological laparoscopic surgery: a randomized controlled study. *Middle East Fertil Soc J.* 2018;23(1):63–67. doi:10.1016/j.mefs.2017.08.005
- Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. *Pain*. 2000;87(2):149–158. doi:10.1016/S0304-3959(00)00276-1
- Huygen FJPM, Kallewaard JW, Nijhuis H, et al. Effectiveness and safety of dorsal root ganglion stimulation for the treatment of chronic pain: a pooled analysis. *Neuromodulation*. 2020;23(2):213–221. doi:10.1111/ner.13074
- 13. Pete DD, D'Souza MS. Local anesthetics. In: *Side Effects of Drugs Annual*. Elsevier; 2020.
- Cherobin ACFP, Tavares GT. Safety of local anesthetics. An Bras Dermatol. 2020;95(1):82–90. doi:10.1016/j.abd.2019.09.025
- 15. Belfrage P, Raabe N, Thalme B, Berlin A. Lumbar epidural analgesia with bupivacaine in labor. Determination of drug concentration and pH in fetal scalp blood, and continuous fetal heart rate monitoring. *Am J Obstet Gynecol.* 1975;121(3):360–365.
- Moore DC, Bridenbaugh LD, Bridenbaugh PO, Tucker GT. Bupivacaine: a review of 2077 cases. J Am Med Assoc. 1970;214 (4):713. doi:10.1001/jama.1970.03180040021003
- Mogensen T, Eliasen K, Ejlersen E, Vegger P, Nielsen IK, Kehlet H. Epidural clonidine enhances postoperative analgesia from a combined low-dose epidural bupivacaine and morphine regimen. *Anesth Analg.* 1992;75(4):607–610. doi:10.1213/00000539-199210000-00025
- Asantila R, Eklund P, Rosenberg PH. Continuous epidural infusion of bupivacaine and morphine for postoperative analgesia after hysterectomy. *Acta Anaesthesiol Scand.* 1991;35(6):513–517. doi:10.1111/j.1399-6576.1991.tb03339.x
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). *J Chin Integr Med.* 2009;7(9):889–896. doi:10.3736/jcim20090918
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. John Wiley & Sons; Vol. Version 5; 2008:1.
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327 (7414):557–560. doi:10.1136/bmj.327.7414.557
- Higgins JP, Altman DG. Assessing Risk of Bias in Included Studies. In: Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series. Wiley-Blackwell; 2008.
- 23. Arden D, Seifert E, Donnellan N, Guido R, Lee T, Mansuria S. Intraperitoneal instillation of bupivacaine for reduction of postoperative pain after laparoscopic hysterectomy: a Double-Blind Randomized Controlled Trial. J Minim Invasive Gynecol. 2013;20(5):620–626. doi:10.1016/j.jmig.2013.03.012

- Badawy AM. intra-peritoneal analgesia to reduce pain after laparoscopic hysterectomy. *Int J Reprod Contracept Obstet Gynecol*. 2017;6(8):3235. doi:10.18203/2320-1770.ijrcog20173444
- 25. Karsli B, Kayacan N, Zorlu G, Arici G, Erman M. The effects of intra-peritoneal tramadol, tenoxicam and bupivacaine on pain relief after laparoscopic gynecological procedures. *Pain Clin.* 2003;15 (3):281–286. doi:10.1163/156856903767650808
- 26. Butala BP, Shah VR, Nived K. Randomized double blind trial of intra-peritoneal instillation of bupivacaine and morphine for pain relief after laparoscopic gynecological surgeries. *Saudi J Anaesth.* 2013;7(1):18–23. doi:10.4103/1658-354X.109800
- Chou YJ, Ou YC, Lan KC, Jawan B, Chang SY, Kung FT. Preemptive analgesia installation during gynecologic laparoscopy: a randomized trial. *J Minim Invasive Gynecol.* 2005;12(4):330–335. doi:10.1016/j.jmig.2005.05.005
- Kayacan N, Arici G, Karsli B, Zorlu G, Erman M. The analgesic efficacy of intra-peritoneal local anaesthetic instillation after laparoscopic gynaecological procedures. *Gynaecol Endosc.* 2002;11 (6):377–381. doi:10.1111/j.1365-2508.2002.00559.x
- Keita H, Benifla JL, Le Bouar V, et al. Prophylactic ip injection of bupivacaine and/or morphine does not improve postoperative analgesia after laparoscopic gynecologic surgery. *Can J Anesth.* 2003;50 (4):362–367. doi:10.1007/BF03021033
- 30. Shalan H, Badawy A, Yousef H, Nazar M. Effect of intra-peritoneal bupivacaine on postoperative pain following laparoscopic pelvic surgery. *Gynaecol Endosc.* 2002;11(6):371–375. doi:10.1111/j.1365-2508.2002.00557.x
- Marks JL, Ata B, Tulandi T. Systematic review and meta analysis of intra-peritoneal instillation of local anesthetics for reduction of pain after gynecologic laparoscopy. *J Minim Invasive Gynecol.* 2012;19 (5):545–553. doi:10.1016/j.jmig.2012.04.002
- Barawi SA, Ahmed Saleh S. Local injection of bupivacaine hydrochloride to reduce postoperative pain in obstetrical and gynaecological surgical incision. J Anesth Clin Res. 2017;8(10). doi:10.4172/ 2155-6148.1000768
- 33. Hortu I, Turkay U, Terzi H, et al. Impact of bupivacaine injection to trocar sites on postoperative pain following laparoscopic hysterectomy: results from a prospective, multicentre, double-blind randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol.* 2020;252:317–322. doi:10.1016/j.ejogrb.2020.07.007
- Kutay Yazici K, Kaya M, Aksu B, Ünver S. The effect of perioperative lidocaine infusion on postoperative pain and postsurgical recovery parameters in gynecologic cancer surgery. *Clin J Pain*. 2021;37 (2):126–132. doi:10.1097/AJP.000000000000000
- Pasqualucci A, De Angelis V, Contardo R, et al. Preemptive analgesia: intra-peritoneal local anesthetic in laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. *Anesthesiology.* 1996;85(1):11–20. doi:10.1097/00000542-199607000-00003
- Labaille T, Mazoit JX, Paqueron X, Franco D, Benhamou D. The clinical efficacy and pharmacokinetics of intra-peritoneal ropivacaine for laparoscopic cholecystectomy. *Anesth Analg.* 2002;94 (1):100–105.
- Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79(2):231–252. doi:10.1016/S0039-6109(05)70381-9

Journal of Pain Research

Dovepress

Publish your work in this journal

The Journal of Pain Research is an international, peer reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. The manuscript

management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http:// www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-pain-research-journal